15:43:31 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Scandinavian Chemotech är ett forskningsbolag. Idag specialiserar sig bolaget inom kemoterapi (ECT) vid behandling utav olika cancerformer. Bolagets produkt baseras på elektrokemoterapi som skickar elektroniska impulser under behandlingen för att lättare kunna nå cellernas DNA och därmed öka möjligheten till en bättre behandling. Behandlingen kan användas för såväl hudcancer som tumörer. Huvudkontoret ligger i Lund.


2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017
2021-10-07 11:44:35

Scandinavian ChemoTech and Vetiqure has taken the opportunity to demonstrate the patented technology, Tumour Specific Electroporation (TSE), at physical trade shows as the restrictions now gradually are being lifted.

Animal Care

Vetiqure, sees a continuous great interest in the TSE technology from several veterinary clinics across northern Europe. As a lot of these clinics are familiar with the older static electroporation, the unique TSE technology is being acknowledged as the next generation with its dynamic feature designed not to damage healthy tissue. A feature that has been greatly appreciated by leading veterinarians.

Since launching the TSE technology to veterinarians several cats and dogs has been treated with promising results.

The feasibility study, which Vetiqure is conducting in the US, is progressing better than expected and has so far shown a true need for this new innovation on the North American market. The progress has been confirmed by our collaborative partner in the US whom is also happy to report that he can see a tremendous interest and curiosity pertaining TSE after our first conference in the US.

Human Care

From the Oncology Convention in Birmingham can be reported that several visiting researchers within the field of electroporation got a true eyeopener when being introduced to our novel setting TSE in this field. Mohan Frick & Professor Bertil R Persson had the opportunity to give an appreciated lecture at the convention.

We also had some in-depth discussions with potential distributors who has shown great interest in distributing our technology.

"After more than 18 months of pandemic barriers our marketing activities have been revived and we can once again visit our customers face to face. It feels really good to start the marketing and training, which after our CE-mark now also includes Europe and other countries acknowledging the certification." - says Mohan Frick, CEO